Notable Labs (NTBLQ) Stock Price

Notable Labs Price

CLOSED
0.00
​
Market closed

Revenue at Notable Labs has contracted by 46.9% per year over the past 6 years to 310,000.00 USD. For Notable Labs, the net margin of -3,633.5% is down versus -3,464.3% a few years ago.

Notable Labs stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs business model & stock analysis

Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline.

Frequently asked questions about Notable Labs

10 analysts currently rate the Notable Labs stock: 8 recommend buying, 2 holding and 0 selling.

Converted at the current exchange rate, the Notable Labs share trades at 0.00 EUR (0.00 USD).

The revenue cannot currently be calculated for Notable Labs.

The profit cannot currently be calculated for Notable Labs.

The P/E ratio cannot be calculated for Notable Labs at the moment.

The P/S cannot be calculated for Notable Labs currently.

The Eulerpool Quality Score for Notable Labs is 2/10.

The ISIN of Notable Labs is IL0012002452. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Notable Labs is NTBLQ. The ticker symbol is used to trade Notable Labs shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
44,285.71 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website vblrx.com
Country
Israel
Currency
USD
Initial public offering
Sep 30, 2014
ISIN
IL0012002452
Cusip
M7517R107
Market capitalization
96.60 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2024
-0.00
P/Ee 2025
-0.00
P/S
P/Se
—
EV/EBIT
0.78
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-72.88 %
Last updated Nov 6, 2026, 10:34 PM

Notable Labs Peer Group

Notable Labs FIGI

NTBL:US · BBG002WK6CM8NTBL:UA · BBG006ND9315NTBL:UC · BBG006ND9324NTBL:UN · BBG006ND9342NTBL:UP · BBG006ND9351NTBL:UB · BBG006ND9379NTBL:UM · BBG006ND9397NTBL:UX · BBG006ND93B4NTBL:UR · BBG006ND93C3NTBL:UD · BBG006ND93J6NTBL:UF · BBG006ND93M2NTBL:VY · BBG006ND93N1